U.S. label record. The cited DailyMed label identifies Leuprolide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
Review source snapshots checked August 19, 2026 · Integrity checked August 19, 2026.
A bounded review of two randomized comparisons involving leuprolide: one pelvic-pain trial and one androgen-deprivation trial using leuprolide as the active comparator.↗↗
What the reviewed sources report
In the reviewed pelvic-pain trial, both treatment groups improved without a significant between-group difference. In the prostate-cancer trial, the oral comparator produced more sustained testosterone suppression than leuprolide; that biochemical endpoint does not establish a difference in cancer survival.↗↗
What remains unresolved?
How do the compared approaches affect long-term patient-important outcomes, harms, and treatment persistence beyond the reviewed follow-up windows?↗↗
The cited injection label covers palliative treatment of advanced prostate cancer. Other leuprolide formulations and gynecologic or pediatric indications require their own product records. Label: indications and usage ↗
Which safety limits matter?
The label describes initial testosterone increases and possible worsening of cancer symptoms, including urinary obstruction or spinal cord compression. It also addresses severe skin reactions, hypersensitivity, hyperglycemia or diabetes, cardiovascular events reported with GnRH agonists, QT prolongation and potential fetal harm. Label: contraindications, warnings, precautions ↗
Label edition and source pins
U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.
Label ZIP SHA-256: 86f3963f5e8c460c7214ef2ac8e45182d3919a279b0fa097bf03eb2c5632471d. Extracted XML SHA-256: 62478327ea5fa12911efbec7eef842d246d0987362191dbd644223838558fcdb.
Reviews summarize selected studies; their scope and limitations are shown above.
European medicine records · 1 products or applications
EMA medicine metadata checked 2026-09-15. These are product-specific centralized records; national European authorizations and full product-information assessments require separate coverage.
Active substance as listed: leuprorelin mesilate. EMA record ↗
Marketing authorisation: 2022-05-24. EMA metadata last updated 2026-05-28. EMA metadata ↗
Application withdrawal and refusal are distinct from marketing authorization. A withdrawal status alone does not establish why it occurred. These metadata entries do not substitute for indication, population or safety details in the relevant product information.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Catalog-name and calibrated alias discovery for human evidence review. Complete query retrieval is separate from clinical eligibility, study-family linkage and appraisal.
2971 retrieved · 2 included · 0 excluded · 2969 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"Leuprolide"[Title/Abstract] OR "leuprorelin"[Title/Abstract] OR "Leuprolide acetate"[Title/Abstract]
Retrieved IDs completely represent this query response, not all relevant literature. Additional aliases, references and non-PubMed sources require separate searches.
Unscreened records may include animal or cell experiments, reviews, secondary analyses, mixtures, protocols and unrelated name matches.
Study-family mappings use available declared registry IDs; unresolved mappings do not create independent trial counts. Full-text, corrections and registry comparison remain separate work.
Showing 25 of 2971 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 32469183 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT03085095.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 21300339 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: leuprolide-PMID21300339-registry-linkage-unresolved.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 42728640 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42719229 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42713047 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42708086 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42700293 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42685950 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42682049 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42617170 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42615454 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42615451 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42613861 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42591741 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42574969 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42529459 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42469731 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42427703 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42423152 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42421559 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42415823 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42406777 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42399824 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42388856 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42369946 — not screened: Name-query match awaiting clinical eligibility screening.
FDA search
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
28 retrieved · 28 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.
Showing 25 of 28 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
FDA ANDA213829 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
FDA NDA205054 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
FDA ANDA075471 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
FDA NDA021731 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
FDA NDA021379 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
FDA ANDA078885 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
FDA NDA021088 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
FDA NDA213150 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
FDA NDA020263 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
FDA NDA203696 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE, NORETHINDRONE ACETATE.
FDA NDA019732 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
FDA NDA219745 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE MESYLATE.
FDA NDA213225 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
FDA NDA021488 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
FDA NDA211488 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE MESYLATE.
FDA NDA020011 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
FDA ANDA217437 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
FDA ANDA215336 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
FDA ANDA074728 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
FDA ANDA212963 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
FDA NDA019010 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
FDA NDA019943 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
FDA ANDA215826 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
FDA NDA020517 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
FDA NDA020708 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LEUPROLIDE ACETATE.
EMA search
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA EMEA/H/C/005034 — include: EMA feed product Camcevi; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA search
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
29 retrieved · 9 included · 0 excluded · 20 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 25 of 29 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA 55292 — include: Document linked by EMA product number; content unappraised. Camcevi : EPAR - Medicine overview
EMA 55296 — include: Document linked by EMA product number; content unappraised. Camcevi : EPAR - Public Assessment Report
EMA 63485 — include: Document linked by EMA product number; content unappraised. Camcevi-H-C-PSUSA-00010877-202307 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
EMA 58657 — include: Document linked by EMA product number; content unappraised. Camcevi : EPAR - Procedural steps taken and scientific information after authorisation (archive)
EMA 67619 — include: Document linked by EMA product number; content unappraised. Camcevi : EPAR - Procedural steps taken and scientific information after authorisation
EMA 73706 — include: Document linked by EMA product number; content unappraised. Camcevi-X-0000258054 : EPAR - Assessment report - Variation
EMA 55297 — include: Document linked by EMA product number; content unappraised. Camcevi : EPAR - Risk management plan
EMA 55294 — include: Document linked by EMA product number; content unappraised. Camcevi : EPAR - All Authorised Presentations
EMA 55293 — include: Document linked by EMA product number; content unappraised. Camcevi : EPAR - Product Information
EMA 4034 — not screened: Title-name match awaiting identity and document review. Leuprorelin: List of nationally authorised medicinal products - PSUSA/00001844/201707
EMA 5467 — not screened: Title-name match awaiting identity and document review. EU/3/16/1821: Public summary of opinion on orphan designation:
Leuprorelin acetate for the treatment of congenital hypogonadotropic hypogonadism
EMA 16609 — not screened: Title-name match awaiting identity and document review. Leuprorelin: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00001844/201707
EMA 44708 — not screened: Title-name match awaiting identity and document review. Leuprorelin-containing depot medicines Article-31 referral - Review of handling errors with depot formulations of leuprorelin medicines started
EMA 44709 — not screened: Title-name match awaiting identity and document review. Leuprorelin-containing depot medicines Article-31 referral - Notification
EMA 44711 — not screened: Title-name match awaiting identity and document review. Leuprorelin-containing depot medicines Article-31 referral - Annex I
EMA 44712 — not screened: Title-name match awaiting identity and document review. Leuprorelin-containing depot medicines Article-31 referral - List of questions
EMA 47674 — not screened: Title-name match awaiting identity and document review. Leuprorelin-containing depot medicines Article-31 referral - PRAC recommends new measures to avoid handling errors
EMA 47675 — not screened: Title-name match awaiting identity and document review. Leuprorelin depot medicines: PRAC recommends new measures to avoid handling errors
EMA 48131 — not screened: Title-name match awaiting identity and document review. Leuprorelin-containing depot medicines Article-31 referral - New measures to avoid handling errors with leuprorelin depot medicines
EMA 48132 — not screened: Title-name match awaiting identity and document review. Leuprorelin-containing depot medicines Article-31 referral - Annex III
EMA 48133 — not screened: Title-name match awaiting identity and document review. Leuprorelin-containing depot medicines Article-31 referral - Timetable for the implementation of the CMDh position (Annex V)
EMA 48134 — not screened: Title-name match awaiting identity and document review. Leuprorelin-containing depot medicinal products: new measures to avoid handling errors with leuprorelin depot medicines
EMA 48468 — not screened: Title-name match awaiting identity and document review. Leuprorelin-containing depot medicines Article-31 referral - Public assessment report to PRAC recommendation
EMA 48520 — not screened: Title-name match awaiting identity and document review. Leuprorelin-containing depot medicines Article-31 referral - Annex II
EMA 48521 — not screened: Title-name match awaiting identity and document review. Leuprorelin-containing depot medicines Article-31 referral - Annex IV
EMA search
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA EU/3/16/1821 — include: EMA orphan feed identifies leuprorelin acetate; designation status: Positive. Orphan designation is not marketing authorization.
ClinicalTrials.gov search
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
544 retrieved · 0 included · 0 excluded · 544 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"Leuprolide" OR "Leuprolide acetate" OR "leuprorelin" OR "Camcevi"
Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
Other registries, unregistered studies and additional aliases remain outside this query.
Showing 25 of 544 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT02023463 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03573648 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03396978 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03263299 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06106932 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00220350 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01669291 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05827081 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00528866 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01269125 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00582556 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00329043 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00936390 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02974270 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05304169 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02319837 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04666129 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07142551 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01717053 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01069094 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01078545 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02393482 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02361905 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00992251 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02689921 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
Read the full Human Evidence Review
Supervised synthesis
What do selected human studies report about Leuprolide?
A bounded review of two randomized comparisons involving leuprolide: one pelvic-pain trial and one androgen-deprivation trial using leuprolide as the active comparator.12
Bottom line from this bounded source set
In the reviewed pelvic-pain trial, both treatment groups improved without a significant between-group difference. In the prostate-cancer trial, the oral comparator produced more sustained testosterone suppression than leuprolide; that biochemical endpoint does not establish a difference in cancer survival.12
Reviewed study record
Endometriosis-associated pelvic-pain trial
Design
A prospective, randomized, double-blind controlled trial compared leuprolide with continuous oral contraceptives over 48 weeks.1
Population
The trial enrolled 47 women with endometriosis-associated pelvic pain at academic medical centers in two U.S. cities.1
Outcomes reported
Pain and depression scores declined significantly from baseline in both groups, while the reported reductions did not differ significantly between groups.1
Limitations
The trial was small, and improvement within each group does not establish that the treatments were equivalent across broader populations or longer follow-up.1
Reviewed study record
HERO androgen-deprivation trial
Design
A sponsor-funded, randomized Phase 3 trial compared oral relugolix with leuprolide for 48 weeks; sustained testosterone suppression was the primary endpoint.2
Population
The trial randomized 930 men with advanced prostate cancer, including 308 assigned to leuprolide.2
Outcomes reported
Sustained testosterone suppression was reported for 96.7% of the relugolix group and 88.8% of the leuprolide group, meeting the trial's noninferiority and superiority criteria for that endpoint.2
Limitations
Leuprolide was the comparator, not the experimental treatment, and the primary result concerned testosterone suppression rather than cancer progression or survival.2
No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1016/j.fertnstert.2011.01.027. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejmoa2004325. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of Leuprolide?
U.S. label record. The cited DailyMed label identifies Leuprolide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.
All four evidence lanes appear in this selected collection, but their presence does not establish completeness, agreement, research quality, safety, effectiveness, approval, availability, or suitability.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
Status at observationCompleted 38Recruiting 5Active, not recruiting 4Not yet recruiting 1
A phase value is unavailable here for 67 selected records; this is not counted as “no phase.”
A status value is unavailable here for 66 selected records; this is not counted as a trial status.
PubMed bibliography
Publication composition
23 of 47 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Publication typesJournal Article 20Clinical Trial 7Randomized Controlled Trial 5Research Support, Non-U.S. Gov't 5English Abstract 4Case Reports 3Letter 3Clinical Trial, Phase II 2Comment 2Research Support, U.S. Gov't, P.H.S. 2Review 2Comparative Study 1Multicenter Study 1
Bibliography fields unavailable here for 24 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
24
FDA Federal Register documents
18
DailyMed SPL versions
6
Canonical profile
Published
Profile structured data
Published
Linked dated records
215
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
PeptideScanner retained ClinicalTrials.gov record NCT07596212 at 2026-09-09T19:17:17.112Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT07801664 at 2026-09-09T19:17:17.074Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was leuprolide.
PubMed lists PMID 16314038 in European urology as Journal Article, with publication-date metadata of 2005-11-15 (day precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Counts and links describe PeptideScanner’s selected records. They are not rankings and do not establish research quality, safety, effectiveness, or medical relevance.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
These dates come from selected source records and PubMed metadata. They are not a complete or continuous timeline of research, safety, approval, or effectiveness.
Evidence summary
What the cited records say
The cited DailyMed label identifies Leuprolide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.
PeptideScanner retained ClinicalTrials.gov record NCT07801664 at 2026-09-09T19:17:17.074Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was leuprolide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07596212 at 2026-09-09T19:17:17.112Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was leuprolide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07455903 at 2026-08-13T05:52:27.015Z. Its registry update date was 2026-08-06, and PeptideScanner's reviewed identity mapping was leuprolide.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 39177865 at 2026-08-10T10:49:06.892Z. PubMed recorded a metadata revision date of 2026-08-04 and an Entrez history date of 2024-08-23. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41824265 at 2026-08-10T10:49:08.794Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-03-13. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained ClinicalTrials.gov record NCT05765500 at 2026-08-10T18:10:03.862Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was leuprolide.↗
PeptideScanner retained ClinicalTrials.gov record NCT04484818 at 2026-08-10T18:10:03.948Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was leuprolide.↗
PeptideScanner retained ClinicalTrials.gov record NCT06169124 at 2026-08-13T05:56:16.370Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was leuprolide.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41712259 at 2026-08-10T18:13:42.694Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2026-02-19. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained ClinicalTrials.gov record NCT06378866 at 2026-08-10T18:10:04.225Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was leuprolide.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42003759 at 2026-08-10T18:13:48.759Z. PubMed recorded a metadata revision date of 2026-07-20 and an Entrez history date of 2026-04-20. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41931341 at 2026-08-10T18:13:46.810Z. PubMed recorded a metadata revision date of 2026-07-14 and an Entrez history date of 2026-04-03. PeptideScanner associated this retained record with the identity slug leuprolide. These dates describe PubMed metadata history, not the article's original publication date.↗